Intellia Therapeutics (NASDAQ:NTLA) Lifted to “Sell” at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a report released on Thursday.

NTLA has been the subject of a number of other research reports. Cantor Fitzgerald reissued an overweight rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th. Citigroup reduced their price objective on Intellia Therapeutics from $31.00 to $29.00 and set a neutral rating for the company in a research note on Friday, May 10th. Truist Financial reissued a buy rating and issued a $120.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th. BMO Capital Markets raised their price objective on Intellia Therapeutics from $62.00 to $70.00 and gave the company an outperform rating in a research note on Friday, May 10th. Finally, Wedbush reissued a neutral rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $69.00.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $22.38 on Thursday. The company has a market cap of $2.16 billion, a P/E ratio of -4.18 and a beta of 1.84. The stock has a 50 day simple moving average of $23.76 and a two-hundred day simple moving average of $26.28. Intellia Therapeutics has a fifty-two week low of $19.37 and a fifty-two week high of $46.50.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The business had revenue of $28.94 million during the quarter, compared to the consensus estimate of $15.60 million. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. On average, research analysts predict that Intellia Therapeutics will post -4.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Opaleye Management Inc. grew its stake in Intellia Therapeutics by 157.6% in the 1st quarter. Opaleye Management Inc. now owns 255,000 shares of the company’s stock valued at $7,015,000 after purchasing an additional 156,000 shares during the period. Virtu Financial LLC bought a new position in Intellia Therapeutics in the 1st quarter valued at $802,000. Comerica Bank grew its stake in Intellia Therapeutics by 853.6% in the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after purchasing an additional 33,214 shares during the period. Bayesian Capital Management LP bought a new position in Intellia Therapeutics in the 1st quarter valued at $303,000. Finally, Axxcess Wealth Management LLC grew its stake in Intellia Therapeutics by 6.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock valued at $457,000 after purchasing an additional 1,010 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.